NMN protects vascular endothelial cells from M1 macrophage-derived IL-1β-induced hyperpermeability by inhibiting VE-cadherin degradation - Takeaways - MDSpire

NMN protects vascular endothelial cells from M1 macrophage-derived IL-1β-induced hyperpermeability by inhibiting VE-cadherin degradation

  • By

  • Takeshi Katayoshi

  • Takahisa Nakajo

  • Natsuko Kitajima

  • Wakana Naka

  • Yuki Kamei

  • Taiki Fushimi

  • Masakatsu Kageyama

  • Mitsugu Akagawa

  • Kentaro Tsuji

  • May 18, 2026

  • 0 min

Share

  • 1

    Nicotinamide mononucleotide (NMN) protects endothelial cells from hyperpermeability induced by M1 macrophages through VE-cadherin preservation.

  • 2

    IL-1β released by M1 macrophages is a key factor in promoting endothelial hyperpermeability.

  • 3

    NMN inhibits IL-1β-induced NF-κB activation, preventing VE-cadherin degradation and maintaining endothelial barrier integrity.

  • 4

    The protective effects of NMN against endothelial dysfunction are dependent on the NAD+-SIRT1 axis.

  • 5

    Other NAD+ precursors, like nicotinamide riboside, also mitigate IL-1β-induced endothelial hyperpermeability.

Original Source(s)

NMN protects vascular endothelial cells from M1 macrophage-derived IL-1β-induced hyperpermeability by inhibiting VE-cadherin degradation

  • by Takeshi Katayoshi, Takahisa Nakajo, Natsuko Kitajima, Wakana Naka, Yuki Kamei, Taiki Fushimi, Masakatsu Kageyama, Mitsugu Akagawa, Kentaro Tsuji

  • May 18, 2026

Related Content

Baptist Health Heart & Vascular Care Expands Interventional Radiology Program with Nine Physicians

 Baptist Health Heart & Vascular Care announces the addition of nine highly skilled interventional radiology physicians to Baptist Health Miami Cardiac & Vascular Institute, part of Baptist Health Heart & Vascular Care, further strengthening its commitment to advanced, minimally invasive care.

  • by

  • April 21, 2026

  • 3 min
Neurofilament Levels Linked to AF Risk

Higher levels associated with stroke, death, and heart failure in long-term cohort

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.